Targeted drug therapy in nonsmall cell lung cancer: clinical significance and possible solutions-part II (role of nanocarriers)

Nonsmall cell lung cancer (NSCLC) accounts for 80-85% of the cases of lung cancer. The conventional therapeutic effective dosage forms used to treat NSCLC are associated with rigid administration schedules, adverse effects, and may be associated with acquired resistance to therapy. Nanocarriers may...

Celý popis

Podrobná bibliografia

Vydané v:	Expert opinion on drug delivery Ročník 18; číslo 1; s. 103 - 118
Hlavní autori:	Yadav, Khushwant S., Upadhya, Archana, Misra, Ambikanandan
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Taylor & Francis 02.01.2021
Predmet:	animal studies cell line studies clinical trials gene delivery Nanocarriers NSCLC gene delivery cell line studies animal studies clinical trials NSCLC Nanocarriers
ISSN:	1742-5247, 1744-7593, 1744-7593
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!